Poll Results

March 2019 Question of the Month

How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?

Higher net costs after the implementation of the proposed rule: 50%

Lower net costs after the implementation of the proposed rule: 12.5%

No impact, net costs will be at the same levels as today: 37.5%

February 2019 Question of the Month

What is the likelihood brand pharmaceutical manufacturers will slow drug price increases in 2019 based on the Trump administration’s proposals?

Highly Likely: 0%

Likely: 12.5%

Unlikely: 75%

Highly Unlikely: 12.5%

January 2019 Question of the Month

Are there more challenges with the new lower priced Repatha NDC compared with the higher priced NDC?

Yes: 57.1%

No: 42.9%

 

Do you think brand manufacturer’s strategy to introduce a lower priced brand NDC of an existing product is going to expand in 2019?

Yes: 85.7%

No: 14.3%

December 2018 Question of the Month

Will there be a(n) ______ number of pharmaceutical product price changes in 2019 compared to 2018?

Increased:  63.64%

Decreased:  0.00%

Similar:  36.36%

November 2018 Question of the Month

Do you believe there are sufficient treatment options for HIV to warrant formulary exclusions?

Yes: 75%

No: 25%

 

Do you believe there are sufficient treatment options for Hemophilia to warrant formulary exclusions?

Yes: 71%

No: 29%

 

Do you believe there are sufficient treatment options for Hereditary Angioedema to warrant formulary exclusions?

Yes: 17%

No: 83%

October 2018 Question of the Month

How will state regulation and licensure of PBMs impact retail pharmacies? (select all that apply)

Improve pharmacy reimbursement rates:  5.88%

Add transparency to Rx reimbursement:  35.29%

Reduce PBM conflict of interests:  17.65%

Eliminate retrospective financial clawbacks:  17.65%

No impact:  11.76%

Reduce pharmacy reimbursement rates:  11.76%

September 2018 Question of the Month

How will the addition of step therapy on Medicare Part B drugs impact biosimilars?

Increase use of biosimilars:  54.55%

No Change:  36.36%

Decrease biosimilar use:  9.09%

August 2018 Question of the Month

Will deeply discounted WAC prices (list price) for biosimilars and specialty generics influence uptake?

Yes: 28.6%

Some impact: 57.1%

No: 14.3%

July 2018 Question of the Month

What is your opinion on pharmacists being allowed to refuse to dispense a prescription for ethical reasons?

Agree: 12.5%

Agree, if they can find another reasonable option for the patient: 56.25%

Disagree: 25%

Indifferent: 6.25%

June 2018 Question of the Month

Do you feel that disclosing the list price of prescription drugs during DTC ads will decrease patient demand for certain products?

Yes: 14.3%

No: 85.7%